Stockreport

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease [Yah...

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the c [Read more]